The impact of the number of cores on tissue microarray studies investigating prostate cancer biomarkers

International Journal of Oncology

Volumn 40, Issue 1, 2012, Pages 261-268

  Tennstedt, Pierre ^a   Köster, Patricia ^a   Brüchmann, Andreas ^a   Mirlacher, Martina ^a   Haese, Alexander ^a   Steuber, Thomas ^a   Sauter, Guido ^a   Huland, Hartwig ^a   Graefen, Markus ^a   Schlomm, Thorsten ^a   Minner, Sarah ^a   Simon, Ronald ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Ki67 LI; p53; Progression; Prostate cancer; Protein; TMA

Indexed keywords

BIOLOGICAL MARKER; KI 67 ANTIGEN; PROSTATE SPECIFIC ANTIGEN; PROTEIN P53;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER TISSUE; CONTROLLED STUDY; GLEASON SCORE; HUMAN; HUMAN TISSUE; LABELING INDEX; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; TISSUE MICROARRAY;

AGED; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROSTATIC NEOPLASMS; PROTEIN ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84455163031     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1216     Document Type: Article

References (33)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer Statistics, 2009. CA Cancer J Clin 59: 225-249, 2009.
2. Eble JN, Sauter G, Epstein JI and Sesterhenn IA (eds.): World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of the Urinary System and Male Genital Organs. IARC Press, Lyon, 2004.
3. Schlomm T, Erbersdobler A, Mirlacher M and Sauter G: Molecular staging of prostate cancer in the year 2007. World J Urol 25: 19-30, 2007.
4. Sauter G, Simon R and Hillan K: Tissue microarrays in drug discovery. Nat Rev Drug Discov 2: 962-972, 2003. (Pubitemid 37540578)
5. Simon R, Atefy R, Wagner U, et al.: HER-2 and TOP2A coamplification in urinary bladder cancer. Int J Cancer 107: 764-772, 2003. (Pubitemid 37339730)
6. Torhorst J, Bucher C, Kononen J, et al.: Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol 159: 2249-2256, 2001. (Pubitemid 33104278)
7. Al-Kuraya K, Schraml P, Sheikh S, et al.: Predominance of high-grade pathway in breast cancer development of Middle East women. Mod Pathol 18: 891-897, 2005. (Pubitemid 41059948)
8. Al-Kuraya K, Schraml P, Torhorst J, et al.: Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res 64: 8534-8540, 2004. (Pubitemid 39552065)
9. Schlomm T, Iwers L, Kirstein P, et al.: Clinical significance of p53 alterations in surgically treated prostate cancers. Mod Pathol 21: 1371-1379, 2008.
10. Fleischmann A, Schlomm T, Huland H, et al.: Distinct subcellular expression patterns of neutral endopeptidase (CD10) in prostate cancer predict diverging clinical courses in surgically treated patients. Clin Cancer Res 14: 7838-7842, 2008.
11. Fleischmann A, Schlomm T, Kollermann J, et al.: Immunological microenvironment in prostate cancer: high mast cell densities are associated with favorable tumor characteristics and good prognosis. Prostate 69: 976-981, 2009
12. Schlomm T, Kirstein P, Iwers L, et al.: Clinical significance of epidermal growth factor receptor protein overexpression and gene copy number gains in prostate cancer. Clin Cancer Res 13: 6579-6584, 2007. (Pubitemid 350206791)
13. Minner S, Jessen B, Stiedenroth L, et al.: Low level HER2 over-expression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer. Clin Cancer Res 16: 1553-1560, 2010.
14. Bubendorf L, Sauter G, Moch H, et al.: Ki67 labelling index: an independent predictor of progression in prostate cancer treated by radical prostatectomy. J Pathol 178: 437-441, 1996. (Pubitemid 26145136)
15. Erbersdobler A, Isbarn H, Steiner I, et al.: Predictive value of prostate-specific antigen expression in prostate cancer: a tissue microarray study. Urology 74: 1169-1173, 2009.
16. El Gammal AT, Bruchmann M, Zustin J, et al.: Chromosome 8p deletions and 8q gains are associated with tumor progression and poor prognosis in prostate cancer. Clin Cancer Res 16: 56-64, 2010.
17. Camp RL, Charette LA and Rimm DL: Validation of tissue microarray technology in breast carcinoma. Lab Invest 80: 1943-1949, 2000. (Pubitemid 32012762)
18. Hoos A, Urist MJ, Stojadinovic A, et al.: Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors. Am J Pathol 158: 1245-1251, 2001. (Pubitemid 32281288)
19. Hoos A, Stojadinovic A, Mastorides S, et al.: High Ki-67 proliferative index predicts disease specific survival in patients with high-risk soft tissue sarcomas. Cancer 92: 869-874, 2001. (Pubitemid 32783075)
20. Hoos A, Stojadinovic A, Singh B, et al.: Clinical significance of molecular expression profiles of Hurthle cell tumors of the thyroid gland analyzed via tissue microarrays. Am J Pathol 160: 175-183, 2002. (Pubitemid 34052278)
21. Engellau J, Akerman M, Anderson H, et al.: Tissue microarray technique in soft tissue sarcoma: immunohistochemical Ki-67 expression in malignant fibrous histiocytoma. Appl Immunohistochem Mol Morphol 9: 358-363, 2001. (Pubitemid 33098147)
22. Fernebro E, Dictor M, Bendahl PO, Ferno M and Nilbert M: Evaluation of the tissue microarray technique for immunohistochemical analysis in rectal cancer. Arch Pathol Lab Med 126: 702-705, 2002. (Pubitemid 34602572)
23. Zhang D, Salto-Tellez M, Putti TC, Do E and Koay ES: Reliability of tissue microarrays in detecting protein expression and gene amplification in breast cancer. Mod Pathol 16: 79-84, 2003. (Pubitemid 36152690)
24. Kristiansen G, Fritzsche FR, Wassermann K, et al.: GOLPH2 protein expression as a novel tissue biomarker for prostate cancer: implications for tissue-based diagnostics. Br J Cancer 99: 939-948, 2008.
25. Rubin MA, Dunn R, Strawderman M and Pienta KJ: Tissue microarray sampling strategy for prostate cancer biomarker analysis. Am J Surg Pathol 26: 312-319, 2002. (Pubitemid 34184454)
26. Bauer JJ, Sesterhenn IA, Mostofi KF, McLeod DG, Srivastava S and Moul JW: p53 nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy. Clin Cancer Res 1: 1295-1300, 1995.
27. Bubendorf L, Kononen J, Koivisto P, et al.: Survey of gene amplifications during prostate cancer progression by high-throughput fluorescence in situ hybridization on tissue microarrays. Cancer Res 59: 803-806, 1999. (Pubitemid 29086730)
28. Singh SS, Qaqish B, Johnson JL, et al.: Sampling strategy for prostate tissue microarrays for Ki-67 and androgen receptor biomarkers. Anal Quant Cytol Histol 26: 194-200, 2004. (Pubitemid 39100905)
29. Zellweger T, Gunther S, Zlobec I, et al.: Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small-volume or low-grade prostate cancer. Int J Cancer 124: 2116-2123, 2009.
30. Vesalainen SL, Lipponen PK, Talja MT, Alhava EM and Syrjanen KJ: Proliferating cell nuclear antigen and p53 expression as prognostic factors in T1-2M0 prostatic adenocarcinoma. Int J Cancer 58: 303-308, 1994. (Pubitemid 24240112)
31. Minner S, Wittmer C, Graefen M, et al.: High level PSMA expression is associated with early psa recurrence in surgically treated prostate cancer. The Prostate 71: 281-288, 2011.
32. Kollermann J, Schlomm T, Bang H, et al.: Expression and prognostic relevance of annexin A3 in prostate cancer. Eur Urol 54: 1314-1323, 2008.
33. Erbersdobler A, Isbarn H, Dix K, et al.: Prognostic value of microvessel density in prostate cancer: a tissue microarray study. World J Urol 28: 687-692, 2010.